ArticleCancer discovery2022

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Andreas Weiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.